Bpci Act

Jan 12, 2017 at 08:21 | Source:
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylans biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.

Photos »

USFDA to review Biocon-Mylan's biosimilar drug for breast cancer
Follow us on
Available On